Obermatt
See Similar Stocks →

Glaukos

NYQ:GKOS · US3773221029
Health Care Equipment & SuppliesMedium

360

31
Profit price91
Owner Earnings Yield1
Dividend Yield1
Price/Sales9
EV / Gross Profit3
Price/Book7
Return on Capital9
Cash Return on Capital10
Return on Equity11
EBIT Margin8
Gross Profitability73
Accruals91
Owner Earnings Margin12
Sales growth87
Profit growth31
Reinvestment91
Price momentum90
Debt load74
Refinancing24
Debt Payback1
Liquidity18
Analyst ratings76
Opinion Changes50
Price Target Upside68
Market mood100
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Glaukos doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryHealth Care Equipment & Supplies
SizeMedium
TypePublic Company
ExchangeNYSE
Founded1998
Employees952
Websiteglaukos.com
ISINUS3773221029
Last UpdateApr 2, 2026
Indices
D.J. US Medical Equipment
Themes
Chronic DiseasesOphthalmologyHealth CareMedicalWellness

Description

Glaukos Corporation (Glaukos) is an ophthalmic pharmaceutical and medical technology company. The company uses Glaukos, the company’s logo, iStent, iStent inject W, iStent infinite, iPrism, iDose TR, iPRIME, MIGS, Avedro, Photrexa, iLink, KXL, Epiox…

Analysis

Middle-of-the-road

Glaukos Corporation sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is solid; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
74
2026

All-time high

74

Jun 2026

All-time low

70

Mar 2026

Average rank

72

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
9
—
—
—
Price/Earnings
100
—
—
—
Price/Book
7
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
12
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Glaukos with its peers
IRIDEX
NAQ:IRIX
69
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Sight Sciences
NSQ:SGHT
44
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Heartbeam
NAQ:BEAT
10
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeX-Small
Full Stock Analysis →
PROCEPT BioRobotics
NMQ:PRCT
19
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
Edwards Lifesciences
NYQ:EW
55
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeX-Large
Full Stock Analysis →
Microbot Medical
NAQ:MBOT
16
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →